齐拉西酮与利培酮治疗男性精神分裂症的临床对照研究  被引量:8

Comparative clinical trial of ziprasidone and risperidone in the treatment of male schizophrenia

在线阅读下载全文

作  者:孙东[1] 江琴普[1] 李建峰[1] 李薇[1] 杨老虎[1] 

机构地区:[1]河北省第六人民医院临床四科,河北保定071000

出  处:《中国临床药理学杂志》2009年第3期204-206,共3页The Chinese Journal of Clinical Pharmacology

摘  要:目的观察齐拉西酮(非典型抗精神病药物)治疗精神分裂症的疗效及安全性。方法将76例精神分裂症患者随机分为齐拉西酮组(38例)和利培酮组(38例),进行临床对照试验,2组治疗剂量分别为80~160、3~6 mg.d-1,疗程8周;用阳性和阴性症状量表(PANSS)评定疗效,用不良反应症状量表(TESS)以及有关实验室检查结果评定安全性。结果治疗结束,较入组时2组评分均显著减低(P<0.01);临床总有效率:齐拉西酮组为86.84%,利培酮组为89.47%,2组比较疗效无显著性差异(P>0.05);齐拉西酮组和利培酮组的不良反应发生率分别为42.11%和47.37%,2组比较差异无显著性(P>0.05),且不良反应均较轻微。结论齐拉西酮是治疗精神分裂症的一种安全、有效的药物。Objective To investigate the efficacy and safety of ziprasidone in the treatment of schizophrenia. Methods Randomly, clinical controlled divided the 76 cases of patients with schizophrenia into the ziprasidone group (38 cases) and the risperidone group (38 cases). Two groups received 8weeks treatment with ziprasidone (80 -160 mg.d^-1) or risperidone ( 3 - 6 mg.d^ -1). The efficacy was evaluated with the change in total score of positive and negative symptom scale (PANSS). The safety was evaluated with sumptom scale (TESS) , the results of laboratory examintion. Results At the end of treatment, both the score of these two groups are significantly lower ( P 〈 0.01 ), the total effective of ziprasidone group was 86.84% and risperidone group was 89.47%. No significant efficacy differences between the two groups ( P 〉 0.05 ). The incidence adverse events of ziprasidone and risperidone were 42. 11% and 47.37% ,also no great difference of overall adverse events, and clinical manifestations are similar ( P 〉 0.05 ) , the adverse events are mild. Conclusion Ziprasidone is an effective and safe drug in treatment of schizophrenia.

关 键 词:精神分裂症 齐拉西酮 利培酮 

分 类 号:R749.3[医药卫生—神经病学与精神病学] R971.41[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象